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Summary
Marginal zone lymphoma represents about 10% of all non-Hodgkin lym-
phomas (NHLs). 33% of patients with acquired angioedema (AAE) due to
acquired C1-inhibitor (C1-INH) deficiency (C1-INH-AAE) have or will
develop NHLs. C1-INH-AAE is a rare condition. We report the follow-up
of 72 C1-INH-AAE patients, followed for a median of 15 years (range 1–
24). Median age was 71 (range 64–79) years; median age at onset of
angioedema symptoms was 575 (range 50–66) years and it was 63 [range
45–80) years at diagnosis]. Twenty patients were diagnosed with low-grade
non-follicular B-cell lymphomas (75% were splenic MZL), one with follicu-
lar and three with high-grade lymphomas (two diffuse large B-cell lym-
phomas and one mantle cell lymphoma). Fifteen NHLs were diagnosed at
onset of AAE or thereafter (3 months to 7 years), eight had already been
diagnosed at onset of angioedema. Two of 24 patients remain on watchful
wait. Thirthen of 24 received chemotherapy, two received rituximab. Three
underwent splenectomy. All 18 patients receiving therapy for NHL experi-
enced post-treatment reduction in AAE symptoms. Our study suggests that
clonal B-cell proliferation is the pathology underlying AAE leading to pro-
duction of C1-INH-neutralizing autoantibodies and to NHLs. The post-
germinal centre origin of NHL suggests that immune stimulation may con-
tribute to lymphomagenesis.
Keywords: acquired angioedema, Non Hodgkin Lymphoma, indolent non-
follicular NHL, Splenic marginal zone lymphomas, antigen-driven lym-
phomagenesis.
Angioedema due to an acquired deficiency of the inhibitor of
the first component of complement (C1-INH) is a rare syn-
drome usually identified as acquired angioedema (AAE). The
clinical features of C1-INH deficiency, which can also be of
genetic origin (hereditary angioedema, HAE), include recur-
rent, self-limiting local swellings involving the upper respira-
tory tract and the gastrointestinal tract with severe abdominal
pain (Zingale et al, 2006). Swelling is due to local accumulation
of bradykinin released from high molecular weight kininogen
upon uncontrolled activation of plasma kallikrein deprived of
its major physiological inhibitor, C1-INH (Cugno et al, 2009).
The precise aetiology of acquired C1-INH deficiency remains
undefined, but the majority of patients have an underlying B-
cell disorder, which appears to be the crucial underlying pathol-
ogy driving the consumption of C1-INH. These B-cell disorders
range from production of anti-C1-INH autoantibodies to mon-
oclonal gammopathies of uncertain significance (MGUS) to
Non-Hodgkin Lymphomas (NLHs) (Cicardi et al, 1996, 2003;
Castelli et al, 2007; Branellec et al, 2012; Lam et al, 2012). The
low levels of C1-INH due to its consumption by pathological
lymphatic tissue or its autoantibody-mediated inactivation are
associated with hyper-activation of the complement or contact
system, which may further consume C1-INH. Standard treat-
ment for AAE attacks is replacement therapy with plasma-
derived C1-INH concentrate (pdC1-INH). However, some
patients with AAE become progressively less responsive to
pdC1-INH treatment (Cicardi et al, 1996; Castelli et al, 2007),
possibly due to anti-C1-INH autoantibody development.
Growing experimental evidence suggests that microenvi-
ronmental interactions driven by inflammatory and infectious
conditions favour the development or promotion of specific
subtypes of indolent non-follicular NHLs (marginal zone
research paper
ª 2016 John Wiley & Sons Ltd, British Journal of Haematology doi: 10.1111/bjh.13908
lymphomas, MZLs; lymphoplasmatycic lymphomas, LPLs;
small lymphocytic lymphomas, SLLs). This evidence suggests
a role for chronic immune stimulation, either from persistent
microbial infections or from autoantigens, in B cell transfor-
mation (Wotherspoon et al, 1991; Franklin et al, 2006).
Further insight on the association between autoimmune
disorders, antigen stimulation and NHL subtypes may help
in understanding the underlying biology of antigen-driven
lymphomagenesis, both in general and specific settings. Here
we report data from our cohort of 72 AAE patients with a
33% rate of lymphoproliferative diseases. Most of them are
indolent non-follicular B cell lymphoproliferative disease
(INFBCLs,) suggesting a likely antigen-driven pathogenetic
mechanism.
Patients and methods
Seventy-two AAE patients were included, 32 of which have
already been described (Castelli et al, 2007). The diagnosis
was based on a history of recurrent angioedema without urti-
caria, which began during or after the fourth decade of life,
absence of family history of angioedema, and plasma levels
of C1-INH function below 50% of normal. Median age at
onset of angioedema symptoms was 575 (range 50–66) years
and diagnosis was made at a median age of 63 (range 55–72)
years. Fifteen of 24 (625%) were diagnosed at onset of AAE
or thereafter (3 months to 7 years). Face oedema was the
most frequent location reported by 83% of patients; 69% of
patients reported peripheral/abdominal attacks and 58%
reported oral mucosa and/or glottis attacks. Seventy nine per
cent of patients had their acute attacks treated with one of
the specific treatments: 86% used pdC1-INH, 46% used Icat-
ibant. C1-INH-auto antibodies were detected in 71% of
patients that used pdC1-INH; 24% of these patients became
non-responsive to pdC1-INH and switched to Icatibant.
Twenty-four of these patients had histologically confirmed
diagnosis of NHL according to the WHO classification
(Swerdlow et al, 2008) Patients were followed for a median
of 15 years (range: 1–24). The following clinical data were
collected from the medical records: patient demographics,
complete blood cell counts, plasma lactic dehydrogenase
(LDH) level, hepatitis B virus (HBV) and hepatitis C virus
(HCV) serology, Ann Arbor Stage, International Prognostic
Index (IPI), Follicular Lymphoma IPI (FLIPI), bone marrow
findings, the presence of B symptoms, Eastern Cooperative
Oncology Group (ECOG) performance status, date of diag-
nosis, type of treatment, treatment response, date of relapse,
date of last follow-up and cause of death and AAE status
after lymphoma treatment.
Complement parameters were determined on serum or
plasma samples stored at 80°C until tested. C1-INH, C4,
C3 and C1q antigens were measured by radial immunodiffu-
sion (Nor Partigen, Low Partigen for C1q Behring, Marburg,
Germany). C1-INH antigenic and C4 were quantified using
radial immunodiffusion or nephelometry; C1-INH function
was measured using a chromogenic or an immunoenzimatic
assay. Results were normalized as a percentage of normal
value (functional C1-INH normal range 70–130%; antigenic
C1-INH normal range 70–115%; antigenic C4 normal range
60–140%). Autoantibodies to C1-INH in serum were mea-
sured by enzyme-linked immunosorbent assay (ELISA) using
the method described by Alsenz et al (1987) with slight mod-
ifications (Alsenz et al, 1987; Cicardi et al, 1996).
Pathological classification of lymphoproliferative disorders
associated with AAE
Haematoxylin–eosin stained slides were reviewed. Immuno-
histochemical staining using CD3, CD20, CD5, CD 10,
CD23, BCL6 and cyclin D1 was performed on the diagnostic
tissue biopsy in all patients with a diagnosis of lymphoprolif-
erative disease. Lymphoproliferative disorders were classified
according to the WHO classification (Swerdlow et al, 2008).
Results
Twenty-four of 72 AAE patients (33%) had an underlying B-
cell NHL. Fifteen of 24 (625%) were diagnosed at onset of
AAE or thereafter (3 months to 7 years). The remaining nine
were diagnosed before the onset of AAE symptoms. Accord-
ing to the WHO classification (Swerdlow et al, 2008), 21
were indolent NHL and three aggressive NHL (two diffuse
large B-cell lymphomas and one mantle cell lymphoma).
Indolent NHLs were splenic MZL (SMZL, n = 15), LPL
(n = 3), SLL (n = 2), follicular lymphoma (n = 1) (Fig 1).
Serological evidence of HCV infection was detected only in 1
AAE patient with NHL. The clinical characteristics of AAE
patients with indolent non-follicular NHL are reported in
Table I.
Autoantibodies to C1-INH were detected in 13 of 24
(54%) NHL patients, including 12/15 (80%) cases with a
diagnosis of SMZL.
Fig 1. Lymphoproliferative diseases according to the World Health
Organization classification in 24 out of 72 acquired angioedema
patients.
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Treatment outcome
Thirteen of the 20 patients with INFBCLs received systemic
therapy alone. Chemotherapy regimens included: non-
anthracycline–containing single agent regimen [chlorambucil
or cyclophosphamide, vincristine and prednisone (CVP)]
and anthracycline-containing regimen [cyclophosphamide,
doxorubicin, vincristine and prednisolone (CHOP)]. Five
patients were treated with bendamustine and rituximab and
achieved complete remission. Two patients received ritux-
imab alone.
All three patients with high-grade malignancies were trea-
ted with anthracycline-containing regimens (CHOP and
Rituximab) and all three died of lymphoproliferative disease
progression.
Three patients were treated with splenectomy alone,
achieving complete remission at 5, 6 and 2 years of follow-
up, respectively. Two patients are still in watchful wait due
to stable disease. One patient with SMZL and concomitant
HCV infection is currently receiving interferon a and rib-
avirin for viral eradication in preparation of possible
chemotherapy. AAE patients did not seem to experience a
significantly different rate of response to treatment as com-
pared to patients with lymphoproliferative disease alone.
All patients treated with chemotherapy achieved, during
therapeutic regimen or during remission, long lasting reduc-
tion of angioedema symptoms. For 12 of 18 patients, pre-
and post-treatment complement parameters were available.
All but one showed post-treatment improvement of comple-
ment abnormalities (Table II).
Discussion
Pathological B-cell proliferation, frequently with clonal char-
acteristics, can lead to acquired C1-INH deficiency and pro-
duction of neutralizing autoantibodies. The bridge between
pathological B-cell clones and C1-INH deficiency is evi-
denced by the presence of monoclonal autoantibodies that
cleave/inactivate C1-INH. When only MGUS or NHL are
present, a cause-effect relationship is supported by: (i)
extraordinarily higher prevalence of MGUS and NHL in AAE
patients compared to the general population; (ii) some
experimental evidence suggesting that lymphatic tissues from
AAE patients fix C1-INH and/or activate the classical com-
plement pathway; (iii) evidence that the M component in
AAE recognizes C1-INH; (iv) scattered reports showing vari-
ous degrees of reversal of the biochemical and/or clinical
abnormalities of AAE upon therapeutically induced remission
of NHL. This report described 24 AAE patients with associ-
ated lymphoproliferative disease, 20 of whom had INFBCLs.
Several lymphoproliferative disorders appear to develop from
transformation of a polyclonal proliferation of lymphocytes
responding to antigenic and/or immunological drivers into a
monoclonal/neoplastic population. This model has emerged
with the description of several lymphomas developing in the
context of chronic antigen-dependent immune stimulation,
as reported for some infectious agents (e.g. H pylori–associ-
ated gastric mucosa-associated lymphoid tissue lymphoma,
HCV-associated lymphoproliferative diseases) or autoim-
mune drivers (e.g. Sj€ogren-associated lymphoproliferative
diseases). In this study, we found that AAE is associated with
an increased risk of NHL compared to general population.
Interestingly, this study also suggests that the risk of lympho-
proliferative disease is confined to specific histotypes that are
rare in the general population (Armitage & Weisenburger,
1998). Our finding is supported by additional scattered
reports showing high prevalence of INFBCL, especially MZL
and SMZL in patients with AAE (Sugisaki et al, 2007; Lam
et al, 2012; Ates et al, 2015).
Our series is the largest reported to date and confirms that
SMZL represents the most common histotype among AAE
patients, with a frequency of 75% of INFBCL (15/20 indolent
lymphoproliferative disease) and of 625% of all lymphopro-
Table I. Clinical Features of 20 AAE patients with indolent non fol-
licular B-cell lymphoma
Median age (range) 64 (45–80)
Gender (male/female) 6/14
Performance Status (ECOG)
0–1 20 (100%)
2–4 0
Ann Arbor Stage
I/II 5 (25%)
III–IV 15 (75%)
B symptoms
Absent 18 (90%)
Present 2 (10%)
Serum LDH levels
Normal 15 (75%)
Elevated 5 (25%)
Unknown 0
Hemoglobin
≥12 g/dl 8 (40%)
≤12 g/dl 12 (60%)
HCV antibody serological test
Negative 19 (95%)
Positive 1 (5%)
Bone marrow involvment
Absent 2 (10%)
Present 17 (85%)
Unknown 1 (5%)
International prognostic index (IPI)
Low/low Intermediate 11 (55%)
High/high intermediate 9 (45%)
Treatment
Chemotherapy 13 (65%)
Rituximab alone 2 (10%)
Radiotherapy 0 (0%)
Watchful wait 2 (10%)
Excision only 3 (15%)
ECOG, Eastern Cooperative Oncology Group; HCV, hepatitis C
virus; LDH, lactic dehydrogenase.
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Table II. Effect of treatment of the lymphoproliferative disease on clinical and biochemical parameters of angioedema due to acquired C1 inhibi-
tor deficiency.
Patient Diagnosis Treatment regimen
*Clinical improvement
of angioedema after
treatment
†Complement
parameters at diagnosis
†Complement parameters
after treatment
1 LPL R-CHOP Complete C1-INH f: <10
C1-INH Ag: 31
C4: <10
C1q: 97
C1-INH f: 116
C1-INH Ag: 115
C4: 146
C1q: 86
2 LPL Rituximab + Fludarabine Complete C1-INH f: <10
C1-INH Ag: <10
C4: <10
C1q: <10
C1-INH f: 30
C1-INH Ag: 50
C4: <10
C1q: 100
3 SLL Chorambucil Complete C1-INH f: <10
C1-INH Ag:<10
C4: <10
C1q: <10
NA
4 SLL Bendamustine+ Rituximab Complete C1-INH f: <10
C1-INH Ag: 9
C4: <10
C1q: 25
C1-INH f: 30
C1-INH Ag: 50
C4: <10
C1q: 100
5 SMZL R-CHOP Complete C1-INH f: <10
C1-INH Ag: <10
C4: <10
C1-INH f: 82
C1-INH Ag: 100
C4: 25
6 SMZL Splenectomy Complete C1-INH f: <10
C1-INH Ag: <10
C4: <10
C1-INH f: 52
C1-INH Ag: NA
C4: <10
7 SMZL CTX Prednisone Complete C1-INH f: 31
C1-INH Ag: 50
C4: <10
NA
8 SMZL R-CVP Complete C1-INH f: <10
C1-INH Ag: <10
C4: <10
C1-INH f: 30
C1-INH Ag: 50
C4: <10
9 SMZL R-CVP Complete C1-INH f: 22
C1-INH Ag: <10
C4: <10
C1-INH f: 82
C1-INH Ag: 90
C4: 60
10 SMZL Splenectomy Complete C1-INH f: 18
C1-INH Ag: <10
C4: 25
C1-INH f: 32
C1-INH Ag: 25
C4: 25
11 SMZL Splenectomy Partial C1-INH f: 18
C1-INH Ag: <10
C4: 25
NA
12 SMZL CTX Prednisone Partial C1-INH f: <10
C1-INH Ag: <10
C4: 25
NA
13 SMZL Rituximab+ Bendamustine Complete C1-INH f: <10
C1-INH Ag: <10
C4: <10
NA
14 SMZL Rituximab+ Bendamustine Complete C1-INH f: 37
C1-INH Ag: <25
C4: <10
C1-INH f: 73
C1-INH Ag: 70
C4: 25
15 SMZL Rituximab+ Bendamustine Complete C1-INH f: <10
C1-INH Ag: <10
C4: <10
NA
16 SMZL Rituximab+ Bendamustine Complete C1-INH f: 33
C1-INH Ag: <10
C4: 25
C1-INH f: 73
C1-INH Ag: 70
C4: 25
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liferative diseases identified. Histologically, the marginal zone
surrounding the follicular areas is expanded and neoplastic
cells have cytological and phenotypical features of marginal
zone lymphocytes, clearly distinguishing them from the lym-
phocytes present in the follicular centre or mantle cell area
(Troussard et al, 1996).
Despite being aware of the undeniable limits of histology,
we speculate that the post-germinal origin of INFBCLs, espe-
cially MZL, might suggest an antigen-driven mechanism of
lymphomagenesis in AAE patients. Some experimental stud-
ies pointed to NOTCH and NF-jB signalling as a strong dri-
ver of autoimmunity and lymphoproliferation and further
research is needed to investigate the role of the activation of
these pathways for lymphomagenesis in our AAE population
(Rossi et al, 2011, 2012).
Next-generation sequencing studies have identified
somatic mutations of myeloid differentiation primary
response 88 (MYD88), a key component of the Toll-like
receptor signalling machinery, in  90% of LPL and in
MZLs. There is evidence to consider MYD88 L265P mutation
as the first genetic hit that induces signalling cascades leading
to NF-jB and JAK-STAT3 activation [with further enhance-
ment due to Bruton tyrosine kinase (BTK) activation]. Addi-
tional genetic and epigenetic hits follow over time, with final
B-cell deregulation and tumour progression (Poulain et al,
2013; Yang et al, 2013).
MYD88 is mutated in a variety of mature B-cell tumours.
Among indolent B-cell malignancies, MYD88 mutations tend
to cluster with LPL/Waldenstr€om macroglobulinaemia, where
they occur in ~90% of cases (Spina et al, 2015). MYD88
mutations are also present in a significant fraction of
IgM-secreting monoclonal gammopathies of undetermined
significance (MGUS), where they are currently detected in
~60–80% of cases, thus pointing to MYD88 mutations as an
early genetic event in the development of lymphoplasmatycic
tumours. Rare MYD 88 mutations are also found in SMZL
and CLL. Among aggressive B-cell malignancies, MYD88
mutations have been identified in ~30% of DLBCL (Fabbri
et al, 2011; Rossi et al, 2012; Xu et al, 2014).
Despite the reported association between INFBCL (espe-
cially MZL and LPL) and HCV infection (Arcaini et al,
2012), in our case series only one patient had HCV infec-
tion.
Autoimmune manifestations, including immune-mediated
pancytopenia, haemolytic anaemia, immune-mediated
thrombocytopenia, skin blistering disease, immune-
mediated neuropathies and autoantibodies to clotting fac-
tors may be included in the lymphoproliferative disorders
(Castelli et al, 2002, 2012; Zhang et al, 2006; Ramchandren
& Lisak, 2010; Seffo & Daw, 2010). MZL and SLL are par-
ticularly frequent in autoimmune manifestations, especially
in MZL patients with a strict IGHV1-2 gene frequency
(Chiorazzi et al, 2005; Hodgson et al, 2011; Brisou et al,
2014).
Autoantibodies to C1-INH were detectable in nine of 15
patients with SMZL, one of who had a concomitant autoim-
mune haemolytic anaemia. This finding suggests that auto
reactivity to this protein is not part of a generic tendency to
autoimmunity, but a specific feature of the disease. Further
investigations are needed to detail the effect of this protein
on lymphocyte proliferation.
In conclusion, our study suggests that B-cell proliferation,
frequently with clonal characteristics, is associated with
acquired C1-INH deficiency and can be responsible for the
production of neutralizing autoantibodies as well as for
increased risk of lymphoproliferative disease. The post-germ-
inal centre origin of most of lymphomas observed in our
population seems to suggest that a chronic immune stimula-
tion may contribute to lymphomagenesis. C1-INH belongs to
the protein family of serine protease inhibitors and under-
goes major structural changes to interact with its target pro-
teases (Silverman et al, 2001). Hence, we speculate that a still
unknown event causes abnormal persistence of hidden
epitopes not recognized as ‘self’ during inhibitor-protease
Table II. (Continued)
Patient Diagnosis Treatment regimen
*Clinical improvement
of angioedema after
treatment
†Complement
parameters at diagnosis
†Complement parameters
after treatment
17 SMZL Rituximab alone Complete C1-INH f: 40
C1-INH Ag: 48
C4: 25
C1-INH f: 71
C1-INH Ag: 100
C4: 50
18 LPL Rituximab alone Complete C1-INH f: 30
C1-INH Ag: 25
C4: 25
C1-INH f: 100
C1-INH Ag: 144
C4: 31
C1-INH f, inhibitor of complement component 1 function; C1-INH Ag, inhibitor of complement component 1 antigen; C4, complement compo-
nent 4; C1q, complement component 1, q subcomponent; LPL, lymphoplasmocytic lymphoma; SLL, small lymphocytic lymphoma; SMZL, splenic
marginal zone lymphoma; R – CHOP, rituximab–cyclophosphamide, doxorubicin, vincristine, prednisone; CEOP, (yclophosphamide, Etoposide,
Prednisolone,Vincristine; R CVP, rituximab,cyclophosphamide, vincristine, prednisone; CVP, cyclophosphamide, vincristine, prednisone; CTX,
Cyclophosphamide; NA, not available.
*Complete: <1 angioedema attack/year. Partial: 50% reduction in attacks frequency compared to pre-treatment.
†Parameters (see text) are expressed as percentage of normal pooled plasma.
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interaction and initiates the autoimmune response that
cross-reacts with the native protein.
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